News
Trial sets up filings for Boehringer IPF drug nerandomilast
With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy O
R&D
Sponsored
Beyond clinical: Boosting recruitment and retention with SDO...
The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.
Market Access
Rare diseases: the urgent need for health equity and acceler...
Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
Oncology
ESMO 2024 - Sven Schaffer
The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.
Sales & Marketing
Sponsored
Launch Excellence: Moments of Truth
The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.
R&D
Partner Content
7th RNA-Targeted Drug Discovery & Development Summit
Optimizing Lead Discovery, Structural Analysis & Preclinical Modeling to Successfully Develop Stable, Effective & Orally Bioavailable Small Molecule RNA Drugs for Robust Translation
R&D
Partner Content
9th CDD For Biologics Summit 2024
Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development
Category :
Views & Analysis
/
